Peginterferon Alfa-2A
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Peginterferon Alfa-2a: From Chronic Hepatitis C to Chronic Hepatitis B
One-Sentence Summary
Peginterferon alfa-2a (DrugBank DB00008, brand name Pegasys) is a pegylated interferon originally developed for chronic hepatitis C treatment. The TxGNN model predicts it may also be effective for Chronic Hepatitis B (hepatitis B virus infection), with 50 clinical trials and 20 publications currently supporting this direction — the strongest evidence base among all ten candidate indications in this evidence pack. Notably, the accompanying rationale indicates this is not a purely novel signal: Peginterferon alfa-2a is already an internationally approved therapy for chronic hepatitis B, so TxGNN has effectively re-identified a known, clinically validated indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Hepatitis C (well-established public drug information; not recorded in the structured evidence pack — see Data Gap DG002) |
| Predicted New Indication | Hepatitis B Virus Infection (Chronic Hepatitis B) |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L1 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the evidence pack (Data Gap DG002, High severity). Based on generally known pharmacological information, Peginterferon alfa-2a is a pegylated form of recombinant interferon alfa-2a. It combines direct antiviral activity (induction of interferon-stimulated genes that suppress viral replication) with immune-modulatory effects (activation of NK cells and promotion of a Th1-skewed immune response that drives HBeAg seroconversion). According to the repurposing rationale supplied with this candidate: "Peginterferon alfa-2a has a dual mechanism — direct antiviral suppression of HBV replication plus immune modulation — which is the core pharmacological basis for HBV treatment. This is an already-approved indication of the drug, not a purely novel prediction."
Chronic hepatitis B and chronic hepatitis C are both hepatotropic viral infections that share overlapping treatment paradigms built around interferon-based antiviral/immunomodulatory therapy. This mechanistic overlap explains why a model trained largely on the drug's hepatitis C evidence base would also surface hepatitis B with very high confidence.
Consistent with this, Peginterferon alfa-2a (Pegasys) is approved for chronic hepatitis B in multiple markets worldwide, and the clinical trial record below shows a mature, decades-long body of Phase 3/4 evidence in HBeAg-positive and HBeAg-negative chronic hepatitis B populations — reinforcing that the TxGNN signal reflects genuine, clinically confirmed pharmacology rather than a speculative repurposing hypothesis.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01011738 | N/A (Observational) | Completed | 1,842 | Large multicenter cohort evaluating on-treatment predictors of response to Pegasys in HBeAg-positive and HBeAg-negative CHB; also assessed efficacy and safety. |
| NCT00435825 | Phase 4 | Completed | 551 | 4-arm RCT comparing PEGASYS 90 vs. 180 mcg for 24 vs. 48 weeks; evaluated HBeAg seroconversion and safety in HBeAg-positive CHB. |
| NCT02604823 | Phase 4 | Completed | 307 | Efficacy and safety of Pegasys in treatment-naive, interferon- or lamivudine-pretreated HBeAg-positive CHB patients (48-week treatment + 24-week follow-up). |
| NCT01086085 | Phase 4 | Completed | 265 | Response-guided treatment study — rapid responders completed 48 weeks total; slow responders randomized to extended Pegasys monotherapy or Pegasys + adefovir. |
| NCT02822547 | Phase 4 | Unknown | 253 | Korean study identifying eligible subjects for a response-guided stopping rule for Pegasys therapy in CHB. |
| NCT00940485 | Phase 4 | Completed | 200 | Compared combination vs. sequential Pegasys + entecavir therapy in HBeAg-positive CHB patients pretreated with entecavir. |
| NCT02908763 | Phase 4 | Unknown | 200 | Investigated ability of peginterferon alpha to achieve HBsAg loss/seroconversion in low-replicative CHB with low HBsAg levels. |
| NCT00973219 | N/A | Completed | 151 | RCT of Peg-IFN + adefovir vs. Peg-IFN + tenofovir vs. no treatment in HBeAg-negative CHB with low viral load. |
| NCT01706575 | Phase 2b | Completed | 76 | Open-label study adding Pegasys to nucleos(t)ide analogue therapy in HBeAg-negative genotype D CHB with stable HBV DNA suppression; evaluated HBsAg decline. |
| NCT00436163 | Phase 4 | Completed | 39 | Baltic post-marketing program evaluating efficacy/safety of Pegasys 180 mcg weekly in treatment-naive HBeAg-positive and -negative CHB. |
Note: 50 trials were retrieved in total for this indication; the 10 most directly relevant, HBV-specific trials are shown above.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15987917 | 2005 | RCT | The New England Journal of Medicine | Landmark trial comparing Peg-IFN alfa-2a alone, Peg-IFN alfa-2a + lamivudine, and lamivudine alone in HBeAg-positive CHB — established the efficacy and safety basis for Peg-IFN alfa-2a in CHB. |
| 30865588 | 2019 | Systematic Review / IPD Meta-analysis | Antiviral Therapy | Individual-participant-data meta-analysis identifying the most appropriate Peg-IFN alfa-2a stopping rules in chronic hepatitis B. |
| 30318613 | 2019 | RCT (Pediatric) | Hepatology | Entecavir + Peg-IFN alfa-2a combination in immune-tolerant, HBeAg-positive children with CHB. |
| 30549279 | 2019 | RCT | Hepatology | Entecavir + Peg-IFN alfa-2a combination in immune-tolerant adults with HBeAg-positive CHB. |
| 18220290 | 2008 | Phase III Registration Trial Analysis | Hepatology | Analysis from a large 271-patient Phase III trial evaluating quantitative HBeAg and HBV DNA as outcome predictors during Peg-IFN alfa-2a therapy. |
| 29715359 | 2018 | Review | JAMA | General review of chronic HBV infection covering epidemiology, natural history, and treatment options including Peg-IFN. |
| 26700861 | 2015 | RCT | Virology Journal | Double-blind trial investigating long-term effects of Peg-IFN alfa-2a therapy in Japanese CHB patients. |
| 33339708 | 2021 | Cohort | Journal of the Formosan Medical Association | Study of virological/immunological predictors of long-term outcomes after Peg-IFN alfa-2a therapy for HBeAg-negative CHB. |
| 31064399 | 2019 | Cohort | Virology Journal | Serum HBV RNA levels evaluated as a predictor of HBeAg seroconversion during Peg-IFN alfa-2a treatment. |
| 21423260 | 2011 | Review | Nature Reviews Gastroenterology & Hepatology | Review of hepatitis B therapy goals (viral suppression, HBeAg seroconversion, HBsAg loss) and treatment response monitoring. |
Note: 20 publications were retrieved in total for this indication; the 10 most relevant (prioritizing RCTs and systematic reviews) are shown above.
Finland Market Information
This drug is currently not marketed in Finland — the evidence pack records 0 authorizations and no license entries. No dosage form, product name, or approved-indication text is available for this jurisdiction.
Safety Considerations
Please refer to the package insert for safety information. No structured safety data (key warnings, contraindications, or drug-drug interactions) was retrievable for this candidate in the current evidence pack — this is flagged as a Blocking data gap (DG001: TFDA/local package insert warnings and contraindications) that must be resolved before any safety evaluation can proceed.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale:
- The predicted indication (chronic hepatitis B) is supported by the highest evidence tier in this pack (L1), including a landmark NEJM RCT, multiple Phase 3/4 studies, and a 1,842-patient observational cohort — and per the repurposing rationale, this is already a clinically established, approved use of the drug rather than a speculative new signal.
- However, the drug currently has zero market authorizations in Finland, and critical safety documentation (package insert warnings/contraindications) is completely missing (Blocking Data Gap DG001), which prevents this candidate from clearing the initial safety screening stage (S1) in this jurisdiction.
To proceed, the following is needed:
- Obtain the official Finland/EU Summary of Product Characteristics (SmPC) or equivalent package insert to resolve DG001 (Blocking) before any safety evaluation.
- Obtain formal mechanism-of-action documentation from DrugBank or the manufacturer to resolve DG002 (High) and support a rigorous mechanistic-plausibility assessment.
- Confirm drug-drug interaction (DDI) data, since the current DDI query returned no results.
- Clarify the regulatory pathway for market authorization in Finland, given the drug is not currently registered there despite established international approval for this indication.
Note: Nine additional candidate indications (ranks 2–10) were also evaluated in this evidence pack — including hepatitis E and hepatitis A virus infection, animal viral hepatitis, and several cardiac conditions — but all scored L3–L5 with weak, indirect, or apparently mismatched evidence (several appear to be ontology-mapping artifacts, e.g., "heart neoplasm" trials that are actually polycythemia vera studies). These are recommended for Hold or, at most, Research Question status and are not detailed further in this report, which focuses on the top-ranked, well-supported candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.